Genetic screening for known SOD1 mutations could be beneficial not only for ALS diagnosis and predicting disease progression, but also for enrollment in clinical trials of SOD1-targeted therapeutics. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.